Search
IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and...
Oct 11, 2024
A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg
He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his...
Oct 10, 2024
Ronald Plasterk introduces us to his new company, Tzu Cancer Therapeutics, and the importance of focusing on circulating tumor cells
After selling his previous company, Frame Therapeutics, to CureVac, the Amsterdam based molecular biologist and entrepreneur wants to...
Oct 9, 2024
Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection
Co-founder and CEO Koenraad Wiedhaup describes the shortcomings of today’s vaccines and why the company has chosen this unique approach....
Oct 9, 2024
Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies
CEO Amir Hefni describes how this autologous product is designed to work, the investments Resolution has made in its manufacturing...
Oct 8, 2024
Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon
Founder and CEO Daniel de Boer describes ProQR's history in Leiden and why it is an ideal spot for a biotech company to be based. Plus,...
Oct 8, 2024
Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'
President & CEO Kevin Pojasek describes how the company searches for these novel cancer-specific antigens that are from areas of the...
Oct 4, 2024
Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA
CEO John Lepore, who was previously head of research at GSK, describes how the company is screening all proteins that are made by...
Oct 3, 2024
Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies - they just had key PoC data
President and CEO Robert Ang describes how Vor knocks out CD33 in transplant cells before they are administered so that patients can...
Oct 2, 2024
Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar
The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor...
Oct 1, 2024
Seattle based Shape Therapeutics is aiming to reprogram cells by delivering guide RNAs via AAV - it has partnerships with Otsuka and Roche
Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA...
Oct 1, 2024
Dyno Therapeutics is using AI to develop next generation AAV vectors for gene therapies
Co-Founder & CSO Adrian Veres and Head of Stewardship Tyson Bertmaring describe the shortcomings of wild type AAV that Dyno is trying to...
Oct 1, 2024
Benchling Co-Founder and CEO Sajith Wickramasekara kicks off Benchtalk 2024 and highlights new feature announcements for this software platform that powers the biotech sector
He describes the three main areas of Benchling's new features: Scaling the wet lab, powering the dry lab, and creating an open platform...
Oct 1, 2024
ARS Pharmaceuticals recently received FDA approval for neffy, epinephrine in a nasal spray format for the treatment of allergic reactions like anaphylaxis
CEO Richard Lowenthal explains the science behind how it works, describes the launch plans, and discusses an additional indication to be...
Sep 30, 2024
Innovation Day San Diego: Palm Therapeutics is focused on developing palmitoylation targeted therapies
Co-Founder and CEO Andrew Rudd describes how the company is focused on this post translational modification as a drug target. The first...
Sep 27, 2024
Innovation Day San Diego: The founder of San Diego based Resolute Science describes how the company aims to use macrophages to deliver toxic payloads to tumors
A resident company of JLABS @ San Diego, Faith Barnett describes how Resolute is creating "Macrophage Targeted Conjugates" to treat...
Sep 27, 2024
Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates
CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized...
Sep 25, 2024
Basel based Anaveon is engineering cytokines to solve the problem of T-cell exhaustion
Co-Founder & CEO Andreas Katopodis describes the company’s three primary programs: a non-specific fusion protein that blocks the alpha...
Sep 25, 2024
Versant Ventures has built a discovery center in Basel called Ridgeline that helps incubate new companies - it has already resulted in successes you will know
Ridgeline president Alex Mayweg and vice president Giorgio Ottaviani describe why the location in Basel and what amenities Ridgeline has...
Sep 24, 2024
Cambridge UK based Constructive Bio announced a $58 million series A today, one of the largest in the UK region
The company is a synthetic bio company that aims to turn living cells into biomanufacturers, for biopharmaceutical purposes and beyond.
Sep 24, 2024
.png){kind=logo}
